Acelot Is Treating Functional Protein Misfolding Diseases Where The Appropriate Therapeutic Mechanism Is A Restoration Of The Normal Protein Homeostasisfunctional Misfolded Proteins Are Found In Various Diseases Such As Alsftdparkinson Sdiabetes And Canceracelot S Platform Combines Generative Aimolecular Dynamics Simulations And Proprietary Assays To Discover Small Molecules That Restore The Homeostasis Of Misfolded Proteins In Various Diseases We Have A Pipeline Of Hit To Lead Discovery Compounds Across Multiple Indicationsalong With An Ind Ready Candidate For Als Our Platform Was Invented By Ucsb Computer Science Professor Drambuj Singhacelot S First Development Candidateace 2223Is A First In Class Orally Bioavailable Small Molecule That Will Undergo Ind Enabling Studies In 2024Ace 2223 Disrupts The Misfolded Forms Of Tdp43 And Restores Functional Tdp43It Acts Upon The Misfolded Conformations Of Tdp43 Found Across Various Patient Populationsincluding Alsftd And Alzheimer S Ace 2223 Has Excellent Brain Penetrance And Adme Propertiesacelot Also Has A Robust Discovery Pipeline
